Financial Performance - The company's operating revenue for Q3 2022 was ¥1,528,951,812.86, representing a year-on-year increase of 15.71%[7] - The net profit attributable to shareholders for the same period was ¥143,336,394.00, a decrease of 3.00% compared to the previous year[7] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥107,773,243.33, down 26.39% year-on-year[7] - The basic earnings per share for Q3 2022 was ¥0.1404, reflecting a decrease of 3.51%[10] - The diluted earnings per share for the same period was also ¥0.1404, with a decrease of 3.51%[10] - The weighted average return on equity was 1.74%, a decrease of 1.34 percentage points compared to the previous year[10] - Net profit for the third quarter of 2022 was ¥410,616,145.90, compared to ¥522,907,828.02 in the same quarter of 2021, reflecting a decrease of approximately 21.4%[37] - The total comprehensive income for the third quarter of 2022 was ¥455,100,926.71, compared to ¥527,924,520.48 in the same quarter of 2021, indicating a decline of approximately 13.8%[41] Assets and Liabilities - Total assets at the end of the reporting period were ¥8,072,279,641.65, an increase of 8.55% from the previous year[10] - The equity attributable to shareholders at the end of the reporting period was ¥5,249,161,364.80, up 6.83% year-on-year[10] - Total liabilities reached RMB 1,807,926,111.28, up from RMB 1,562,752,238.50, which is an increase of approximately 15.7%[32] - The company's equity increased to RMB 6,264,353,530.37 from RMB 5,873,853,182.78, reflecting a growth of about 6.6%[32] - The total assets and shareholders' equity amounted to ¥8,072,279,641.65 and ¥6,264,353,530.37 respectively, showing an increase from ¥7,436,605,421.28 and ¥5,873,853,182.78 in the previous year[34] Cash Flow - The net cash flow from operating activities was -$329.69 million, a significant decline compared to $10.48 million in the previous period[43] - Total cash inflow from operating activities amounted to $3.58 billion, while cash outflow was $3.91 billion, resulting in a net cash flow deficit[43] - Cash inflow from financing activities reached $398.44 million, primarily driven by $272.41 million in borrowed funds[45] - Cash outflow for financing activities totaled $342.37 million, leading to a net cash flow of $56.07 million from financing activities[45] - The company reported a cash and cash equivalents balance of $718.87 million at the end of the period, down from $1.20 billion at the beginning[45] Operating Costs and Expenses - Total operating revenue for the first three quarters of 2022 reached ¥4,125,458,242.24, an increase from ¥3,905,489,465.23 in the same period of 2021, representing a growth of approximately 5.6%[34] - Total operating costs for the first three quarters of 2022 were ¥3,787,650,893.48, up from ¥3,453,125,606.14 in 2021, indicating an increase of about 9.7%[34] - Research and development expenses for the first three quarters of 2022 were ¥80,494,632.44, down from ¥93,814,952.29 in 2021, a decrease of about 14.2%[34] - The company reported an investment income of ¥79,440,998.92 for the first three quarters of 2022, compared to ¥145,961,683.62 in the same period of 2021, a decline of approximately 45.5%[34] - The company reported a financial expense of -¥7,935,554.07 in the first three quarters of 2022, compared to -¥2,529,638.14 in the same period of 2021, indicating a significant increase in financial costs[34] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 28,147[19] - The company's cash and cash equivalents decreased to RMB 733,483,087.45 from RMB 1,230,032,968.52, representing a decline of approximately 40.5%[25] - Accounts receivable increased significantly to RMB 1,067,283,207.46 from RMB 542,570,625.19, marking an increase of around 96.5%[25] - Inventory levels rose to RMB 903,446,319.21 compared to RMB 879,086,482.25, showing a slight increase of about 2.7%[29] - The retained earnings increased to RMB 3,188,170,336.72 from RMB 2,942,103,018.19, representing a growth of approximately 8.4%[32]

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the first half of 2022, representing a year-on-year increase of 15%[16]. - The net profit attributable to shareholders reached RMB 300 million, up 20% compared to the same period last year[16]. - Future guidance estimates a revenue growth of 10-15% for the full year 2022[16]. - The company's operating revenue for the first half of the year was ¥2,596,506,429.38, representing a year-on-year increase of 0.48% compared to ¥2,584,126,942.38 in the same period last year[21]. - The net profit attributable to shareholders decreased by 18.86% year-on-year, amounting to ¥257,108,118.47, primarily due to a significant reduction in investment income from joint ventures and a decline in gross profit from the main business due to a sluggish livestock market[22]. - The net cash flow from operating activities decreased by 62.17% year-on-year, resulting in a negative cash flow of ¥405,281,593.71, attributed to an increase in sales amounts not yet settled[21]. - Basic earnings per share decreased by 18.94% to ¥0.2529, reflecting the decline in net profit attributable to shareholders[22]. - The total comprehensive income for the first half of 2022 was ¥302,523,918.50, compared to ¥361,988,151.17 in the same period of 2021, representing a decrease of 16.38%[141]. Market Expansion and Strategy - User data indicates a growth in active users by 25%, reaching a total of 5 million active users[16]. - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share by the end of 2023[16]. - New product launches are expected to contribute an additional RMB 200 million in revenue for the second half of 2022[16]. - The company plans to focus on improving cash flow management and optimizing product offerings in response to market challenges[22]. - The company has expanded its product strategy to address rising feed raw material prices, launching new products to meet market demand[41]. Research and Development - The company is investing RMB 50 million in R&D for new technologies aimed at improving product efficiency[16]. - The company emphasizes innovation in its core product lines, focusing on "medicine, feed, and vaccines," which has significantly enhanced its independent innovation capabilities[33]. - The company is engaged in the research and development of new feed varieties and technologies, indicating a focus on innovation[176]. Financial Position and Assets - The company has maintained a strong cash position with cash reserves of RMB 500 million as of June 30, 2022[16]. - The total assets at the end of the reporting period were ¥7,929,345,719.44, an increase of 9.65% from the previous year-end[21]. - The net assets attributable to shareholders increased by 8.97% to ¥5,235,782,363.26 compared to the previous year-end[21]. - Total current assets increased to CNY 3,264,196,886.43 from CNY 2,839,932,650.33, representing a growth of approximately 15%[124]. - Cash and cash equivalents decreased to CNY 783,883,054.30 from CNY 1,230,032,968.52, representing a decline of approximately 36%[124]. Risks and Challenges - The management highlighted potential risks including regulatory changes and market competition[16]. - The company is addressing risks related to major animal epidemics and market competition by enhancing sales strategies and providing personalized technical services to clients[54]. - The company has identified risks from abnormal fluctuations in exchange rates, which could impact procurement timing and profit margins, and plans to strengthen market tracking and cost control[57]. Corporate Governance and Shareholder Relations - The company did not distribute dividends or increase capital reserves in the latest financial period, maintaining a conservative approach to profit allocation[64]. - The company has implemented stock option incentive plans, adjusting the exercise price and the list of incentive targets in 2022[65]. - The company held two shareholder meetings in 2022, utilizing both on-site and online voting methods[62]. - The company has committed to strictly reduce related party transactions and ensure that any unavoidable transactions are conducted fairly and transparently[83]. Environmental and Social Responsibility - Two subsidiaries, Zhongmu Anda and Inner Mongolia Zhongmu, are classified as key pollutant discharge units by environmental protection authorities, with total pollutant emissions of 2.418 tons (COD) and 0.154 tons (ammonia nitrogen) respectively[69]. - Inner Mongolia Zhongmu has signed a wastewater treatment cooperation agreement, ensuring that wastewater meets the "Urban Wastewater Reuse Industrial Water Quality Standards" after treatment[70]. - The company invested CNY 378,000 in poverty alleviation and rural revitalization efforts, including donations of agricultural machinery and maintenance of local farms[80].

Financial Performance - The company's operating revenue for Q1 2022 was ¥1,123,215,357.53, a decrease of 12.93% compared to the same period last year[5] - Net profit attributable to shareholders was ¥134,110,195.38, down 17.06% year-on-year[5] - Basic earnings per share were ¥0.1320, reflecting a decrease of 17.09% year-on-year[5] - Total operating revenue for Q1 2022 was approximately $1.12 billion, a decrease of 13% compared to $1.29 billion in Q1 2021[30] - Net profit for Q1 2022 was approximately $140.53 million, a decrease of 22.1% from $180.53 million in Q1 2021[32] Cash Flow - The net cash flow from operating activities was -¥261,001,755.79, an increase of 15.71% compared to the previous year[5] - Cash flow from operating activities for Q1 2022 was negative at approximately -$261 million, compared to -$225 million in Q1 2021[36] - Net cash flow from investing activities was -112,522,587.31, compared to -26,822,088.85 in the previous period[38] - Cash inflow from financing activities totaled 94,992,101.57, up from 30,725,246.20 in the prior period[38] - Net cash flow from financing activities was 30,445,666.79, compared to 10,125,733.71 in the last period[38] - The net increase in cash and cash equivalents was -342,936,872.22, compared to -242,246,762.06 in the previous period[38] - The ending balance of cash and cash equivalents was 861,785,216.50, compared to 770,073,268.47 at the end of the previous period[38] Assets and Liabilities - Total assets at the end of the reporting period were ¥7,770,576,517.08, an increase of 4.49% from the end of the previous year[5] - Total liabilities amounted to CNY 1,732,227,637.18, up from CNY 1,562,752,238.50, indicating an increase of approximately 10.9%[26] - The company's total equity increased to CNY 6,038,348,879.90 from CNY 5,873,853,182.78, showing a growth of about 2.8%[26] - As of March 31, 2022, total current assets amounted to CNY 3,090,088,287.82, an increase from CNY 2,839,932,650.33 in the previous year[21] - Total non-current assets reached CNY 4,680,488,229.26, compared to CNY 4,596,672,770.95 in the previous year[24] Shareholder Equity - Shareholders' equity attributable to shareholders was ¥5,071,376,309.04, up 3.21% compared to the previous year[8] - The company’s retained earnings grew to CNY 3,076,213,213.57 from CNY 2,942,103,018.19, an increase of approximately 4.6%[26] Expenses - Research and development expenses for Q1 2022 were approximately $23.85 million, slightly down from $24.89 million in Q1 2021[30] - Sales expenses for Q1 2022 decreased to approximately $59.65 million from $91.53 million in Q1 2021, a reduction of 34.7%[30] - Management expenses for Q1 2022 were approximately $63.30 million, down from $70.21 million in Q1 2021[30] Other Financial Metrics - The weighted average return on net assets was 2.26%, a decrease of 1.28 percentage points year-on-year[5] - Other income rose by 292.68%, mainly due to increased government subsidies related to R&D projects[12] - The company reported a significant increase in prepayments by 187.64%, primarily due to increased supplier procurement prepayments[12] - Short-term borrowings increased by 44.38%, mainly due to increased short-term bank credit loans[12] - Accounts receivable rose significantly to CNY 897,551,899.54, up from CNY 542,570,625.19, indicating a growth of approximately 65.5%[21] - Inventory increased to CNY 935,473,713.35 from CNY 879,086,482.25, reflecting a growth of about 6.4%[21] - The company reported a significant increase in other receivables, which rose to CNY 44,922,303.54 from CNY 34,358,964.06, a growth of approximately 30.7%[21] - Short-term borrowings increased to CNY 166,039,461.74 from CNY 115,000,000.00, reflecting a growth of about 44.5%[24] - Investment income for Q1 2022 was approximately $25.20 million, a decrease from $65.80 million in Q1 2021[30] - Other comprehensive income after tax for Q1 2022 was approximately $22.90 million, significantly higher than $6.86 million in Q1 2021[32] Accounting Standards - The company has adopted new accounting standards starting from 2022[38]

Financial Performance - The company's operating revenue for 2021 was CNY 5,301,571,718.27, an increase of 6.06% compared to 2020[17]. - Net profit attributable to shareholders for 2021 was CNY 513,861,040.88, reflecting a year-on-year increase of 22.22%[17]. - The net cash flow from operating activities decreased by 42.50% to CNY 382,997,571.22 in 2021[17]. - Basic earnings per share for 2021 rose to CNY 0.5060, a 21.99% increase from the previous year[17]. - The company's total assets at the end of 2021 were CNY 7,436,605,421.28, up 9.92% from 2020[17]. - The weighted average return on equity increased to 10.84%, up 1.23 percentage points from 2020[17]. - The company's operating revenue for the reporting period was 5.302 billion RMB, with a net profit of 587 million RMB, and a net profit attributable to the parent company of 514 million RMB, resulting in a basic earnings per share of 0.5060 RMB[41]. - Total costs and expenses amounted to 4.795 billion RMB, representing 90.44% of the operating revenue[41]. Dividend Distribution - The company plans to distribute a cash dividend of 1.52 RMB per 10 shares, totaling 154,372,811.35 RMB based on the total share capital of 1,015,610,601 shares as of the end of 2021[4]. - The company implemented a cash dividend policy, distributing a total of 126,951,325.13 CNY in cash dividends, which is approximately 30.20% of the net profit attributable to shareholders for 2020[149]. Audit and Compliance - The company received a standard unqualified audit report from Zhongshun Yatai Accounting Firm, ensuring the authenticity and completeness of the financial report[4]. - There were no non-operating fund occupations by controlling shareholders or their related parties during the reporting period[4]. - The company has not violated decision-making procedures for providing guarantees to external parties[4]. - The company has established a comprehensive internal control system aimed at risk management and compliance, with no significant internal control deficiencies reported for the year 2021[153]. - The company maintained a standard unqualified opinion in its internal control audit report for the year 2021[154]. Market Position and Strategy - The company maintained a leading market share in government procurement for foot-and-mouth disease and avian influenza vaccines, ensuring stable market positioning[27]. - The company expanded its customer base significantly, with a focus on large clients in the feed sector, leading to major breakthroughs in customer development[28]. - The company is positioned as a key player in China's animal epidemic prevention system, actively participating in national disease control efforts[37]. - The company is adapting to regulatory changes, including the new veterinary GMP requirements, to enhance industry concentration and promote transformation and upgrading[42]. - The company is focused on reducing diarrhea rates in piglets through the development of antibiotic-free feed[75]. Research and Development - The company has implemented an innovative R&D mechanism, receiving over 100 research applications through its open research project fund, enhancing its R&D capabilities[37]. - The company's R&D investment amounted to 20,699.72 million RMB, representing 13.09% of operating revenue and 3.93% of net assets[84]. - Major R&D projects include the development of vaccines with investments of 396.72 million RMB for foot-and-mouth disease and 293.37 million RMB for porcine circovirus vaccines, showing a year-on-year increase of 87.89%[87]. - The company is actively engaged in the research and development of various new veterinary vaccines and diagnostic kits[75]. Environmental Responsibility - The company’s environmental protection facilities are fully operational, with all wastewater and emissions meeting regulatory standards[159]. - The total COD emissions from the subsidiary Zhongmu Anda were reported at 5.88 tons, with a concentration of 233.4 mg/L, well below the standard of 500 mg/L[155]. - The company has signed a wastewater treatment agreement with a treatment company to ensure compliance with the fermentation pharmaceutical industry wastewater discharge standards[159]. - The company has received multiple environmental impact assessment approvals for various projects, including a significant project approved in September 2021[163]. - The company has implemented a pollution prevention and control system, with all solid waste disposed of according to regulations[159]. Corporate Governance - The total pre-tax compensation for the board members and senior management amounted to 4,758,380 CNY[119]. - The company has established a remuneration and assessment committee to oversee the remuneration decisions for directors and senior management[127]. - The company’s board of directors and supervisory board remuneration is approved by the shareholders' meeting and determined based on national regulations and industry standards[127]. - The company has a strategic committee that includes members responsible for overseeing long-term strategic planning[136]. Investment and Expansion - The company plans to invest CNY 454.1 million in the construction of the Nanjing Biomedical Industrial Park project[131]. - A capital increase of CNY 250 million will be made to the wholly-owned subsidiary Inner Mongolia Zhongmu to enhance its profitability and core competitiveness[131]. - The company plans to enhance its market presence and enhance product offerings in response to increased demand in the pharmaceutical sector[46]. - The company is set to establish a wholly-owned subsidiary with an investment of CNY 100 million in Shandong Province[131]. Employee and Workforce Management - The company reported a total of 4,197 employees, with 2,011 in the parent company and 2,186 in major subsidiaries[142]. - The company has established a comprehensive training system covering all levels of employees to enhance professional skills and meet human resource needs[144]. - The company has a performance-based compensation policy aimed at maximizing the value of human resource investments[143]. - The company has a total of 343 employees with a master's degree or higher, indicating a strong educational background among its workforce[142].

Revenue and Profit - Revenue for the third quarter was 1,321,362,522.85 yuan, a decrease of 3.34% compared to the same period last year[6] - Net profit attributable to shareholders of the listed company for the third quarter was 147,772,189.07 yuan, an increase of 11.13% year-on-year[6] - Total operating revenue for the first three quarters of 2021 was 3,905,489,465.23 RMB, an increase from 3,649,512,937.17 RMB in the same period of 2020[30] - Net profit for the first three quarters of 2021 was 522,907,828.02 RMB, slightly up from 515,065,392.70 RMB in the same period of 2020[33] - Total comprehensive income for the first three quarters of 2021 was 527,924,520.48 RMB, up from 502,872,033.89 RMB in the same period of 2020[33] - Basic earnings per share for the first three quarters of 2021 were 0.4575 RMB, compared to 0.4777 RMB in the same period of 2020[33] Assets and Liabilities - Total assets as of the end of the reporting period were 7,229,924,218.42 yuan, an increase of 6.86% compared to the end of the previous year[10] - Total assets increased to RMB 7,229,924,218.42 in Q3 2021, up from RMB 6,765,641,842.11 at the end of 2020[24] - Current assets totaled RMB 2,967,286,290.23, compared to RMB 2,743,622,934.95 at the end of 2020[20] - Long-term equity investments grew to RMB 868,636,877.18, up from RMB 800,591,062.94 at the end of 2020[24] - Fixed assets increased to RMB 2,092,267,562.26, compared to RMB 1,619,097,376.13 at the end of 2020[24] - Total liabilities rose to RMB 1,456,412,694.74, up from RMB 1,396,384,154.45 at the end of 2020[26] - Shareholders' equity increased to RMB 5,773,511,523.68, compared to RMB 5,369,257,687.66 at the end of 2020[26] - Accounts receivable surged to RMB 879,194,779.76, up from RMB 403,849,655.93 at the end of 2020[20] - Inventory grew to RMB 785,846,266.07, compared to RMB 708,494,164.59 at the end of 2020[20] - Short-term borrowings increased to RMB 115,000,000.00, up from RMB 90,000,000.00 at the end of 2020[24] - Retained earnings rose to RMB 2,928,837,084.12, compared to RMB 2,591,149,249.48 at the end of 2020[26] - Total assets stood at 6.77 billion yuan, with current assets accounting for 2.74 billion yuan and non-current assets at 4.02 billion yuan[41][43] - Total liabilities were 1.26 billion yuan, with current liabilities making up 1.19 billion yuan and non-current liabilities at 66.30 million yuan[43] - The company held 1.05 billion yuan in monetary funds and 300 million yuan in trading financial assets as of the beginning of 2021[41] - Accounts receivable amounted to 403.85 million yuan, while inventory stood at 708.49 million yuan[41] - Fixed assets totaled 1.62 billion yuan, with intangible assets at 671.09 million yuan[43] - Long-term equity investments were valued at 800.59 million yuan[41] - Total liabilities amount to 1,396,384,154.45[46] - Total non-current liabilities are 203,778,271.84[46] - Deferred income is 40,484,618.14[46] - Deferred tax liabilities stand at 16,660,014.95[46] - Total equity attributable to the parent company is 4,482,430,509.67[46] - Minority interests amount to 886,827,177.99[46] - Total equity is 5,369,257,687.66[46] - Total liabilities and equity are 6,765,641,842.11[46] Cash Flow - Net cash flow from operating activities for the period from the beginning of the year to the end of the reporting period was 10,475,214.83 yuan, a decrease of 94.95% year-on-year[6] - The company's operating cash flow decreased significantly due to increased cash expenses, bid deposits, and unit receivables compared to the same period last year[12] - Cash received from sales of goods and services for the first three quarters of 2021 was 3,442,578,124.69 RMB, up from 3,151,087,004.07 RMB in the same period of 2020[35] - Cash paid for goods and services for the first three quarters of 2021 was 2,499,252,364.43 RMB, compared to 2,205,657,370.38 RMB in the same period of 2020[35] - Total cash inflows from operating activities for the first three quarters of 2021 were 3,553,340,589.68 RMB, up from 3,249,562,509.10 RMB in the same period of 2020[35] - Operating cash flow decreased significantly to 10.48 million yuan from 207.42 million yuan in the previous period[38] - Investment cash flow turned positive at 75.80 million yuan, compared to a negative 181.36 million yuan previously[38] - Financing cash flow was negative at 92.91 million yuan, down from a positive 2.30 million yuan[38] - Net increase in cash and cash equivalents was negative 5.30 million yuan, compared to a positive 29.48 million yuan previously[41] Shareholders and Equity - Weighted average return on equity (ROE) for the third quarter was 3.08%, an increase of 0.15 percentage points compared to the same period last year[10] - Non-recurring gains and losses for the third quarter amounted to 1,353,828.24 yuan[12] - The total number of ordinary shareholders at the end of the reporting period was 47,650[13] - The largest shareholder, China Animal Husbandry Group Co., Ltd., held 504,094,163 shares, accounting for 49.63% of the total shares[13] - The National Social Security Fund 502 Portfolio held 11,866,658 shares, accounting for 1.17% of the total shares[13] Operating Costs and Expenses - Operating costs for the first three quarters of 2021 were 3,453,125,606.14 RMB, compared to 3,356,119,288.34 RMB in the same period of 2020[30] - R&D expenses for the first three quarters of 2021 decreased to 93,814,952.29 RMB from 108,874,818.11 RMB in the same period of 2020[30] - Investment income for the first three quarters of 2021 was 145,961,683.62 RMB, down from 321,912,190.16 RMB in the same period of 2020[30]

股票代码：600195 股票简称：中牧股份 编号：临 2021-039 | --- | --- | |----------------------------------------------------------------------|-------| | | | | 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 | | | 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 | | 为进一步加强与广大投资者的沟通交流，中牧实业股份有限公司（以下简称"公 司"）将参加由北京上市公司协会、上证所信息网络有限公司共同举办的"2021 年 北京辖区上市公司投资者集体接待日"活动，现将有关事项公告如下： 本次集体接待日活动时间为 2021 年 9 月 23 日（星期四）15:00 至 17:00，将在 上证所信息网络有限公司提供的网上平台，采取网络远程的方式举行，投资者可以 登录"上证路演中心"网站（http://roadshow.sseinfo.com）或关注微信公众号"上 证路演中心"，参与本次投资者集体接待日活动。 届时公司的总经理吴冬荀先生、董事会秘书郭亮先生、 ...

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the first half of 2021, representing a year-on-year increase of 15%[14]. - Net profit attributable to shareholders reached RMB 300 million, up 20% compared to the same period last year[14]. - The company’s gross margin improved to 35%, an increase of 5 percentage points year-on-year[14]. - The company's operating revenue for the first half of the year reached ¥2,584,126,942.38, representing a year-on-year increase of 13.21%[21]. - The net profit attributable to shareholders decreased by 10.02% to ¥316,866,970.60, primarily due to the impact of stock reduction from the previous year[22]. - The net cash flow from operating activities showed a significant decline, amounting to -¥249,913,498.64, compared to a positive cash flow of ¥99,758,086.88 in the same period last year[21]. - Basic earnings per share decreased by 10.01% to ¥0.3120, influenced by the previous year's stock reduction[22]. - The company reported a 37.31% increase in net profit after deducting non-recurring gains and losses, reaching ¥314,192,820.75[21]. - The company reported a total revenue of 5,353.19 million RMB for the first half of 2021, representing a year-on-year increase of 21.33%[50]. - The net profit attributable to shareholders for the reporting period was 364,462.26 million RMB, showing significant growth compared to previous periods[50]. Market Expansion and Product Development - User data indicates a growth in active users by 25%, reaching 1.5 million users by the end of June 2021[14]. - The company plans to launch two new products in Q3 2021, focusing on innovative animal health solutions[14]. - Market expansion efforts include entering three new provinces, aiming for a 10% market share in these regions by the end of 2021[14]. - The company has allocated RMB 100 million for R&D in new technologies related to animal pharmaceuticals[14]. - The company plans to continue expanding its market presence and investing in new product development to capitalize on industry growth trends[22]. - The company has successfully implemented a "one province, one policy" marketing strategy for government procurement, actively participating in all regional bidding activities[35]. - The company has launched new high-margin product lines and adjusted its product structure in response to market demand, enhancing its overall profitability[35]. Industry Trends and Risks - Risk factors include potential regulatory changes and market competition, which could impact future performance[14]. - The livestock industry showed stable growth, with national meat production increasing by 23% year-on-year, totaling 42.91 million tons[29]. - The ongoing African swine fever epidemic poses a significant risk, potentially leading to a loss of customers and reduced production capacity for feed companies[54]. - The company is facing industry risks due to fluctuations in raw material prices, particularly corn and soybean meal, which are critical for the feed industry[52]. Financial Position and Assets - The company's total assets increased by 6.89% to ¥7,231,740,962.72, while net assets attributable to shareholders rose by 7.19% to ¥4,804,687,912.43[21]. - The company's fixed assets increased by 33.76% to ¥2,165,690,114.42, mainly due to the completion of major infrastructure projects related to biosecurity[45]. - The accounts receivable rose by 125.77% to ¥911,759,548.05, indicating an increase in sales on credit[45]. - The total assets at the beginning of the period were 5,369,257,687.66, demonstrating a solid asset base[145]. - The total assets of Qianyuanhao are reported at 99,333.19 million RMB, with a net profit of 4,010.15 million RMB for the reporting period[50]. Environmental and Social Responsibility - The company has invested CNY 170,000 in environmental technology upgrades to ensure compliance with environmental regulations[77]. - The company has established a comprehensive environmental monitoring plan, conducting six air quality tests in the first half of 2021[75]. - The company has committed to fulfilling its political, economic, and social responsibilities as a central enterprise, focusing on supporting rural revitalization and consolidating poverty alleviation achievements[80]. - The company has achieved compliance with national pollution discharge standards, with no exceedances reported[68]. Governance and Compliance - The company has strengthened its compliance management system, integrating compliance review into major decision-making processes and enhancing internal control mechanisms[38]. - The company has undergone changes in its board of directors, with new independent directors elected to strengthen governance[60]. - The company has not reported any significant litigation or arbitration matters during the reporting period[89]. - The company has committed to ensuring fair and transparent practices in related transactions to protect the interests of all shareholders[83]. Cash Flow and Financing Activities - The company’s cash flow from operating activities showed a net outflow of ¥249,913,498.64, a significant change from a net inflow of ¥99,758,086.88 in the previous year[42]. - The company’s investment activities generated a net cash inflow of ¥96,335,548.36, a significant improvement compared to a net outflow of ¥104,240,403.98 in the previous year[42]. - Cash inflow from operating activities totaled CNY 2,170,043,500.15, an increase of 7.4% compared to CNY 2,020,257,910.78 in the same period last year[135]. - The company reported a net cash decrease of CNY -115,876,177.25, contrasting with an increase of CNY 49,517,482.18 in the previous year[138]. Research and Development - The company has received over 100 research and development applications through its established industry-academia-research platform, facilitating significant collaboration in innovation[36]. - The company’s research and development expenses decreased by 6.02% to ¥59,108,621.60, reflecting a reduction in management costs[42]. - Research and development expenses for the first half of 2021 were ¥59,108,621.60, a decrease from ¥62,895,139.78 in the first half of 2020[123]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 52,128[96]. - The largest shareholder, China Animal Husbandry Industry Group Co., Ltd., holds 504,094,163 shares, accounting for 49.63% of the total shares[96]. - The company did not distribute any dividends or bonus shares for every 10 shares, with a distribution of 0[64].

Financial Performance - Net profit attributable to shareholders increased by 24.50% to CNY 161,690,274.69 year-on-year[17] - Operating revenue rose by 20.66% to CNY 1,289,969,743.11 compared to the same period last year[17] - Basic earnings per share increased by 24.47% to CNY 0.1592[17] - The net profit after deducting non-recurring gains and losses increased by 23.42% to CNY 159,593,834.98[17] - Comprehensive income for Q1 2021 was ¥187,397,932.59, compared to ¥135,796,860.16 in Q1 2020, reflecting a growth of 37.9%[53] - Net profit for Q1 2021 was ¥180,534,702.52, representing a 36.0% increase compared to ¥132,807,959.95 in Q1 2020[53] - Earnings attributable to shareholders of the parent company for Q1 2021 were ¥161,690,274.69, up from ¥129,873,427.75 in Q1 2020, marking a 24.5% increase[53] Assets and Liabilities - Total assets increased by 4.49% to CNY 7,069,335,139.08 compared to the end of the previous year[17] - Total liabilities reached ¥1,511,585,971.97, up from ¥1,396,384,154.45, indicating an increase of about 8.2%[41] - Current liabilities rose to ¥1,307,138,928.66, compared to ¥1,192,605,882.61, indicating an increase of approximately 9.6%[39] - Non-current assets totaled ¥4,162,195,519.61, an increase from ¥4,022,018,907.16, reflecting a rise of about 3.5%[39] - Total equity reached ¥5,557,749,167.11, compared to ¥5,369,257,687.66, reflecting a growth of approximately 3.5%[41] Cash Flow - Net cash flow from operating activities decreased by 327.63% to -CNY 225,566,084.27 compared to the same period last year[17] - Cash inflow from operating activities was CNY 903,350,395.28 in Q1 2021, compared to CNY 820,705,936.64 in Q1 2020, representing an increase of 10.1%[63] - The company reported a net cash outflow from operating activities of CNY -225,566,084.27 in Q1 2021, a decline from a net inflow of CNY 99,093,327.71 in Q1 2020[63] - Cash paid for purchasing goods and services increased by 65.80% to RMB 814.16 million, reflecting higher operational needs[29] - Cash paid for other operating activities increased by 80.74% to RMB 143.25 million, mainly due to reduced guarantee and petty cash payments from the previous year[29] Shareholder Information - The total number of shareholders at the end of the reporting period was 57,231[24] - The largest shareholder, China Animal Husbandry Group Co., Ltd., holds 49.63% of the shares[24] Other Financial Metrics - The weighted average return on equity increased by 0.44 percentage points to 3.54%[17] - Government subsidies recognized in the current period amounted to CNY 2,498,706.96[19] - Financial expenses increased by 151.03% to RMB 898.68 thousand, mainly due to exchange losses and interest expenses[29] - Investment income rose by 36.14% to RMB 65.80 million, primarily from equity method recognition[29] - Research and development expenses for Q1 2021 totaled ¥24,894,429.31, an increase from ¥22,186,971.31 in Q1 2020[51] - The company is focused on expanding its market presence and enhancing product development strategies[75]

Financial Performance - Operating income for the first nine months was CNY 3,629,503,537.73, representing a year-on-year growth of 22.83%[17] - Net profit attributable to shareholders was CNY 486,088,018.07, up 78.82% from the same period last year[17] - The net profit after deducting non-recurring gains and losses was CNY 377,153,422.70, an increase of 41.10% year-on-year[17] - Basic earnings per share for the period was CNY 0.4799, reflecting a growth of 78.47% compared to the previous year[19] - Total operating revenue for Q3 2020 reached ¥1,359,358,371.05, an increase of 21.4% compared to ¥1,119,431,138.48 in Q3 2019[56] - Net profit for Q3 2020 reached ¥97.69 million, compared to ¥89.99 million in Q3 2019, reflecting an increase of 8.5%[63] - The company reported a total comprehensive income of approximately ¥136.50 million for Q3 2020, compared to ¥505.57 million in Q3 2019[60] Assets and Liabilities - Total assets at the end of the reporting period reached CNY 6,441,832,265.98, an increase of 13.20% compared to the end of the previous year[17] - The company's total equity as of September 30, 2020, was CNY 5,102,553,710.65, compared to CNY 4,639,189,557.82 at the end of 2019, representing a growth of about 10%[46] - The company's total liabilities amounted to CNY 1,339,278,555.33, up from CNY 1,051,250,206.88, reflecting an increase of approximately 27.4%[46] - Total current liabilities increased to CNY 1,195,002,015.54 from CNY 960,251,372.99, which is an increase of approximately 24.5%[46] - The total assets increased to ¥5,008,964,538.28 in Q3 2020, compared to ¥4,489,718,621.40 in Q3 2019, marking a growth of 11.6%[52] - The total liabilities rose to ¥743,949,602.63 in Q3 2020, up from ¥583,230,515.57 in Q3 2019, reflecting a 27.6% increase[52] Cash Flow - Cash flow from operating activities for the first nine months was CNY 207,859,464.08, a significant recovery from a negative cash flow of CNY -300,658,372.63 in the same period last year[17] - Cash inflow from operating activities for the first three quarters of 2020 was approximately ¥3.13 billion, up from ¥2.47 billion in the same period of 2019, representing an increase of about 26.9%[64] - Net cash flow from operating activities for Q3 2020 was negative at approximately -¥26.16 million, an improvement from -¥312.46 million in Q3 2019[71] - Cash inflow from investment activities for Q3 2020 was approximately ¥948.73 million, down from ¥2.20 billion in Q3 2019, indicating a decrease of about 57.0%[68] - The ending cash and cash equivalents balance for Q3 2020 was approximately ¥709.35 million, compared to ¥382.98 million at the end of Q3 2019, showing an increase of about 85.0%[68] Shareholder Information - The total number of shareholders at the end of the reporting period was 40,074[21] - The largest shareholder, China Animal Husbandry Group Co., Ltd., held 49.63% of the shares[21] Investments and Income - Investment income surged by 118.94% to RMB 321.91 million, mainly from the reduction of shares in Jindaiwei[28] - The company received cash from investment activities amounting to RMB 182.73 million, a 1,690.18% increase due to the sale of Jindaiwei shares[30] - The company reported a significant increase in other receivables, which reached CNY 75,104,671.69, compared to CNY 43,149,053.65 in the previous year, marking an increase of about 74.1%[40] Operational Metrics - The weighted average return on equity increased by 4.54 percentage points to 11.17%[17] - Research and development expenses for Q3 2020 amounted to ¥39,473,703.36, slightly down from ¥42,283,613.87 in Q3 2019[56] - The company’s investment income for Q3 2020 was ¥70.59 million, compared to ¥43.61 million in Q3 2019, showing a significant growth in investment performance[61] Other Financial Metrics - Tax payable rose by 154.27% to RMB 64.25 million, driven by increased profits[28] - The company reported a government subsidy of CNY 6,303,797.97 during the period, which is closely related to its normal business operations[19] - Estimated compensation for the brucellosis antibody positive incident is RMB 35 million, which has been accrued[33] - The company is actively cooperating with local government departments to manage the aftermath of the brucellosis incident[32]

股票代码：600195 股票简称：中牧股份 编号：临 2020-036 中牧实业股份有限公司 关于参加北京辖区上市公司投资者 集体接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 为进一步加强与广大投资者的沟通交流，中牧实业股份有限公司（以下简称"公 司"）将参加由北京上市公司协会、上证所信息网络有限公司共同举办的"2020 年 北京辖区上市公司投资者集体接待日"活动，现将有关事项公告如下： 本次集体接待日活动时间为 2020 年 9 月 8 日（星期二）15:00 至 17:00，将在 上证所信息网络有限公司提供的网上平台，采取网络远程的方式举行，投资者可以 登录"上证路演中心"网站（http://roadshow.sseinfo.com）或关注微信公众号"上 证路演中心"，参与本次投资者集体接待日活动。 届时公司的总经理吴冬荀先生、董事会秘书郭亮先生、总会计师（财务负责人） 黄金鑑先生将通过网络在线交流形式与投资者就公司治理、发展战略、经营状况和 可持续发展等投资者关注的问题进行沟通。 欢迎广大投资者 ...